






NEW ORAL ANTICOAGULANTS (NOACs)

Rivaroxaban, dabigatran and apixaban are commonly referred to as the NOACs and are used as alternatives to older anticoagulant agents, such as warfarin and enoxaparin (Clexane®)

RIVAROXABAN	DABIGATRAN	APIXABAN
Indication		
Prophylaxis of VTE after elective hip or knee replacement surgery Prevention of stroke and systemic embolism in AF with one or more risk factors		
Treatment of DVT and PE, and prophylaxis of recurrent DVT and PE in adults	-	-
Tablet strength available		
<ul style="list-style-type: none"> 10mg 15mg 20mg 	<ul style="list-style-type: none"> 75mg 110mg 150mg 	<ul style="list-style-type: none"> 2.5mg 5mg 
Swallowing difficulty		
The tablet may be crushed and mixed with water or apple puree immediately prior to use and administered orally.	DO NOT OPEN CAPSULES (increased risk of bleeding)	The tablet can be crushed (not currently licensed)
Enteral feeding tubes		
The crushed tablet should be administered in a small amount of water via a gastric tube after which it should be flushed with water	DO NOT OPEN CAPSULES (increased risk of bleeding and beads may block the tube)	The tablet can be crushed and administered via gastric tube (not currently licensed)
These drugs should not be used with other anticoagulants!		
These drugs should be used with caution in patients on antiplatelets, such as aspirin, clopidogrel, ticagrelor and dipyridamole		
Monitoring and Side effects		
<ul style="list-style-type: none"> Haemorrhage - monitor for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs Nausea and vomiting Dyspepsia 		